New polymorphs of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino- methyl)-phenylamino]-methyl-1-methyl-1h-benzimidazole-5-carbonyl) -pyridin-2-yl-amino]-propionate
AssigneeBoehringer Ingelheim Pharma GMBH & CO.KG
InventorsMihaela Pop, Jaroslaw Mazurek, Mimoun Lamkadmi
Life of this patent
Estimating the term…
Abstract
The invention relates to new polymorphs of the active substance ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate, the preparation thereof and the use thereof as pharmaceutical compositions.
Claims29
Ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate in crystalline form, characterised by a melting point of Tmp.=128±3° C. (anhydrous form III) (determined by DSC;
- evaluated by peak maximum;
- heating rate:
- 10° C./min).
Ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate in crystalline form, characterised by a melting point of Tmp.=133±3° C. (anhydrous form IV) (determined by DSC;
- evaluated by peak maximum;
- heating rate:
- 10° C./min).
Ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate tetrahydrate in crystalline form, characterised by a melting point of Tmp.=128±5° C. with simultaneous release of the crystal water enclosed in the crystal lattice (monohydrate I) (determined by DSC;
- evaluated by peak maximum;
- heating rate:
- 10° C./min).
Ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate tetrahydrate in crystalline form, characterised by a melting point of Tmp.=128±5° C. with simultaneous release of the crystal water enclosed in the crystal lattice (monohydrate II) (determined by DSC;
- evaluated by peak maximum;
- heating rate:
- 10° C./min).
Ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate tetrahydrate in crystalline form, characterised by a melting point of Tmp.=123±5° C. with simultaneous release of the crystal water enclosed in the crystal lattice (solvate I) (determined by DSC;
- evaluated by peak maximum;
- heating rate:
- 10° C./min).
Process for preparing the anhydrous form III of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate, characterised in that
- a) ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate base is dissolved in a solvent mixture of diisopropylether/THF=60:40 at 60° C. with a concentration of approx. 120 mg/ml,
- b) the solution is cooled at a cooling rate of 1° C./h to a temperature of approx. 25° C. and left to stand for a further 72 h,
- c) the precipitated crystals are suction filtered, and
- d) the product thus obtained is dried at ambient temperature.
Process for preparing the anhydrous form IV of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate, characterised in that
- ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate base is dissolved in 1,4-dioxane at ambient temperature with a concentration of approx. 120 mg/ml,
- b) the solution is left to equilibrate for 2 h with stirring at ambient temperature and then filtered off,
- c) hexane (as antisolvent) is added to the clear solution at ambient temperature in a molar ratio of 1:1 to 1,4-dioxane,
- d) the precipitated crystals are suction filtered and
- e) the product thus obtained is dried at ambient temperature.
Method of preparing the monohydrate I of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate, characterised in that
- a) ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate base is dissolved in a solvent mixture of DMSO/cyclohexanone=80:20 at 60° C. with a concentration of approx. 120 mg/ml,
- b) the solution is cooled at a cooling rate of 1° C./h to a temperature of approx. 5° C. and left to stand for a further 24 h at this temperature,
- c) the precipitated crystals are suction filtered and
- d) the product thus obtained is dried at ambient temperature.
Method of preparing the monohydrate II of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate, characterised in that
- a) ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate base is dissolved in a solvent mixture of acetonitrile/acetone=60:40 at 60° C. with a concentration of approx. 60 mg/ml,
- b) the solution is cooled at a cooling rate of 1° C./h to a temperature of approx. 5° C. and left to stand for a further 24 h at this temperature,
- c) the precipitated crystals are suction filtered and
- d) the product thus obtained is dried at ambient temperature.
Method of preparing the solvate I of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate, characterised in that
- a) ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate base is suspended in nitrobenzene at 50° C. with a concentration of approx. 333 mg/ml,
- b) the suspension is filtered hot (50° C.) and the resulting saturated solution is cooled to a temperature of approx. 20° C. at a cooling rate of 30° C./h to and left to stand for a further 24 h,
- c) optionally, in the event that no crystals are formed within these 24 h, the solution is evaporated down until crystallisation sets in,
- d) the precipitated crystals are suction filtered and
- d) the product thus obtained is dried at ambient temperature.
Dependencies are inferred from the claim text.